Glioblastoma multiforme is the most common brain tumor in adults. Because of its highly invasive nature, it is not easy to treat, resulting in high mortality rates. Stromal interacting molecule 1 (Stim1) plays important roles in regulating storeoperated Ca 2+ entry, and controls invasion by cancer cells.
Glioblastoma multiforme (GBM), with an approximately 60% prevalence of grade IV gliomas, is the most common malignant primary brain tumor in the adult central nervous system (CNS) and has a poor prognosis (Urbanska et al. 2014) . The median survival time is less than 12 months. Since GBM are highly mobile and invasive resulting in tumor recurrence (Cuddapah et al. 2014) , typical therapies such as surgery, radiation, and chemotherapy only add months of additional survival. A better understanding of the mechanisms of glioma invasion is crucial for future GBM therapies and drug development.
The ubiquitous store-operated Ca 2+ entry (SOCE) pathway, initiated by the depletion of intracellular Ca 2+ stores, plays an important role in many fundamental physiological processes, especially in the non-excitable cells such as mast cells, T cells and different types of cancer cells (Di Capite and Parekh 2009; Yang et al. 2009; Hou et al. 2011; Xie et al. 2016) . The stromal interacting molecule 1 (STIM1), an endoplasmic reticular Ca 2+ sensor protein, interacts with the Orai1 protein via aggregating in discrete areas of junctional endoplasmic reticular-plasma membranes, resulting in activation of the SOCE pathway (Jardin and Rosado 2016) . Since the physiological functions of Stim1 were evaluated to be a critical regulator in carcinogenesis and cancer progression, Stim1 is considered as a novel target for cancer therapy (Vashisht et al. 2015; Wong and Chang 2015) . In gliomas, suppression of Stim1 induces cell apoptosis and cell-cycle arrest (Liu et al. 2011; Li et al. 2013) . Down-regulation of Stim1 also caused a dramatic decrease in glioma cell invasion (Motiani et al. 2013) , suggesting that STIM1 may play an oncogenic role in glioma progression, and may also be a future therapeutic target in GBM diseases.
Flavonoids, purified from traditional herbal medicines, were identified to possess anti-inflammatory and anticancer activities. Because of their ability to easily traverse the blood-brain barrier in vivo (Youdim et al. 2004) , several flavonoids, including xanthohumol (XN), offer therapeutic benefits for cancer therapy. XN (3 0 -[3,3-dimethyl allyl]-2 0 ,4 0 ,4-trihydroxy-6 0 -methoxychalcone), a principal prenylated flavonoid, is isolated from hop flowers (Humulus lupulus L. of the Cannabaceae) (Stevens and Page 2004) . XN has multiple bioactivities in preventing the development of many diseases, and is also characterized as a broad-spectrum cancer chemo-preventive agent (Kim et al. 2013; Viola et al. 2013) . Previous studies suggested that XN treatment significantly induced glioma cell apoptotic death (Festa et al. 2011; Zajc et al. 2012) and autophagy (Lu et al. 2015) . Although XN can abolish cell invasion in breast, colon, and prostate cancers (Vene et al. 2012; Wang et al. 2012b) , the effects and mechanisms of XN on regulating glioma cell invasion are still unclear.
Previous studies reported that the Stim1 signaling is essential for glioma invasion (Motiani et al. 2013; Zhu et al. 2014) . XN can influence several invasive-related signaling (Arnaiz-Cot et al. 2017) , but no studies have reported the effects of XN on Stim1 gene expression or glioma cell invasion. Furthermore, our previous studies indicated that miR-4725-3p was up-regulated from the miRNA profile of XN-treated U87-MG cells (Chen et al. 2016) . Using bioinformatics tools, Stim1 was predicted to be a direct target gene of miR-4725-3p. However, relationships among XN, Stim1, and miR-4725-3p in regulating glioma cell invasion remain unknown. In this study, we identified that the functional role of miR-4725-3p in targeting of Stim1 expression which in turn suppress the glioma cell invasion.
Materials and methods
This study was not pre-registered.
Chemicals and reagents
Human glioblastoma U87-MG (research resource identifier, RRID: CVCL_0022), M059K (RRID:CVCL_0401), and Hs-683 (RRID: CVCL_0844) cells were purchased from the Bioresource Collection and Research Center (Hsinchu City, Taiwan). Primary human astrocytes (cat. no. N7805100; RRID not registered) were purchased from Thermo Fisher Scientific (Waltham, MA, USA). Other cell culture-related reagents were purchased from GIBCO-BRL (Grand Island, NY, USA). Anti-Stim1 (cat. no. 4916; RRID:AB_2271287), ERK (cat. no. 9102; RRID not registered), phospho-ERK (cat. no. 9101; RRID not registered), c-Fos (cat. no. 2250; RRID: AB_2247211), and phospho-c-Fos (cat. no. 5348; RRID: AB_10557109) antibodies were purchased from Cell Signaling Technology (Danvers, MA, USA). An anti-b-actin (cat. no. GTX109639; RRID: AB_10725604) antibody was purchased from GeneTex (Hsinchu City, Taiwan Survival analysis of GBM patients from TCGA Clinical information and RNA-sequencing (RNA-Seq) data of GBM patients (n = 153) were obtained from the UCSC cancer browser (https://genome-cancer.ucsc.edu/). RNA-Seq data were normalized by RNA-Seq by expectation maximization and were log2-transformed. Survival analyses were conducted by dividing patients into high-and low-STIM1 groups based on different quartile points of Stim1 gene expression. Then, different survival rates between these two groups were evaluated by a log-rank test and Cox regression with forward selection.
Differential gene expression and pathway enrichment analyses
Differential gene expression analyses were carried out using the limma package (Bioconductor version 3.6) (Ritchie et al. 2015) . Genes, stratified by third quartiles of Stim1 expression levels, were considered to be significant with a false discovery rate (FDR) of < 0.05 by comparing the high-and low-Stim1 groups. To clarify the pathway enriched in patients with high Stim1 expression, upregulated candidates (with an FDR of < 0.05 and a multiple of change of ≥ 1.5) were applied to the DAVID functional annotation tool (da . Using this tool with the Kyoto Encyclopedia of Genes and Genomes database, pathways enriched in the high-STIM1 group with an FDR of < 0.05 were identified. In addition, a gene set enrichment analysis (GSEA) was also conducted. Genes were ranked from top to bottom based on the product of the log2 multiple of change and negative log10 p value. Then, pathways from the Hallmark database were chosen for analysis. Weighted Kolmogorov-Smirnov tests were performed with 10 4 permutations to calculate the normalized enrichment score and FDR.
miRNA array analyses, target genes, and c-Fos-binding site predictions The miRNA expression profiling was performed in our previous study (Chen et al. 2016) All target genes of miR-4725-3p were predicted using miRwalk (Dweep et al. 2011) and TargetScan (Lewis et al. 2005) . The putative c-Fos-binding site in the miR-4725 promoter was predicted by the JASPAR database (Mathelier et al. 2016) . Construction of full-length miR-4725-3p-, Stim1-, Stim1-3U-, and Stim1-3UM-over-expressing plasmids Using a PCR amplification of 500 ng cDNA on a GeneAmp PCR system 9700 (Applied Biosystems) with primers listed in Table 1 , miR-4725-3p, Stim1, Stim1-3U, and Stim1-3UM genes were, respectively, generated to construct plasmids. The following thermal profile was used: an initial denaturation step at 95°C for 5 min, followed by 40 cycles of 94°C for 1 min, 58°C for 1 min, and 72°C for 1 min, with a final extension at 72°C for 10 min. PCR products were analyzed by agarose gel electrophoresis. All PCR products were cloned into pCDH or pcDNA3.1 plasmids and sequenced.
Matrigel invasion assays
The transwell inserts (25 mm polycarbonate membrane, 8 lm pore size; cat. no. PI8P01250; Millipore) coated with Matrigel matrix (cat. no. 356234; Corning) were used to conduct Matrigel invasion assays. The 5 9 10 4 cells were placed in the top chamber of transwell migration chamber after, respectively, treating with the indicated dose of XN or transfecting with the indicated over- Table 1 Primer list
Primer name Sequence
For promoter cloning miR-4725-prom2000-
STIM1 shRNA CCGGCCACTCACAGTGGTTCTGTTTCTCGAGAAACAGAACCACTGTGAGTGGTTTTTTG c-Fos shRNA CCGGGCGGAGACAGACCAACTAGAACTCGAGTTCTAGTTGGTCTGTCTCCGCTTTTT Sequence of microRNA inhibitor miR-4725-3p inhibitor CCCGACACUGACGCCUUCCCCA microRNA inhibitor negative control CAGUACUUUUGUGUAGUACAA expressing plasmids. After 24 h, no migrated cells in the upper chamber were removed with a cotton swab from the upper surface of the transwell membrane. Migrating cells on the lower membrane surface were fixed in 100% methanol (À20°C for 15 min), stained, photographed, and counted with a microscope at 1009 magnification. Experiments were assayed in triplicate, and at least four fields were counted in each experiment by three researchers who are randomly selected and blinded to treatment conditions. Statistical analysis was carried out using unpaired t' test, one-or two-way ANOVA with Tukey-Kramer multiple-comparison test.
Construction of the Stim1 3 0 UTR reporter plasmid and mutagenesis
Using U87 MG genomic DNA as a template, the PCR to amplify Stim1 3 0 UTR fragments was performed using sets of primers specific listed in Table 1 . PCR products were cloned into the pMIRGLO-REPORT luciferase vector (cat. no. E1330; Promega). After sequencing, these vectors were named pMIRGLO-Stim1-3U. An overlap extension PCR was sued to carry out mutagenesis of the miR-4725-3p target site in the Stim1 3 0 UTR, and these vectors were named pMIRGLO-Stim1-3UM. For the reporter assays, Lipofectamine 3000 (Invitrogen) was used to transiently transfect wild-type or mutant reporter plasmids, and the miR-4725-3p plasmids into cells. After 24 h incubation, the Luciferase Assay System (Promega) was used to perform reporter assays. The dual Renilla luciferase value was used as an internal control.
Construction of the miR-4725 promoter reporter plasmid and mutagenesis Several reporter constructs were produced to test the effect of XN on regulating miR-4725 promoter activity. A PCR using primers listed in Table 1 was used to amplify a 2-kb fragment of the miR-4725 promoter (chr17:31569142-31571141). The PCR product was cloned into the pGL3 reporter vector (cat. no. E1751; Promega) after digesting with XhoI and HindIII, creating the expression vector pGL3-miR-4725-prom. Using pGL3-miR-4725-prom as a template, pGL3-miR-4725-1.5K, pGL3-miR-4725-1K, and pGL3-miR-4725-0.5K were, respectively, isolated through a PCR. To mutate the c-Fos-binding site in the miR-4725 promoter, an overlap extension PCR was used, and named pGL3-miR-4725-prom-MUT. For reporter assays, different sizes of wild-type or mutant reporter plasmids using Lipofectamine 3000 (Invitrogen) were transiently transfected into cells, and then treated with XN. The pNL1.1-TK plasmids were co-transfected and served as an internal control. The reporter assay was performed with the Nano-Glo dual luciferase assay system (Promega) after 24 h transfection.
Chromatin immunoprecipitation (ChIP) assay
According to the manufacturer's instructions (EZ-ChIP TM , cat. no. 17-295; Millipore), ChIP assays were performed. Briefly, 10 6 cells with or without XN treatment were fixed with 1% formaldehyde. After washing with cold PBS, cells were lysed in a buffer. Nuclei were sonicated to shear the DNA, and lysates were pelleted and precleared. One microgram of the c-Fos antibody was used to incubate with protein-DNA complexes overnight, and then incubated with protein G beads, followed by elution in 1% SDS/0.1 M NaHCO 3 and reverse cross-linked at 65°C. A negative control [mouse immunoglobulin G (IgG)] and positive control (an anti-RNA-Pol antibody) provided by the manufacturer were used to compare with DNA recovered from samples containing the c-Fos antibody. Finally, after recovery, DNA was subjected to a PCR analysis. PCR primers are listed in Table 1 .
Statistical analysis
Statistical analyses were carried out using Sigma Plot 12.5 (Systat Software, San Diego, CA, USA). No sample calculation was performed. No Outliers were excluded from the analysis. In invasion experiments, the people who conducted the experiments on cell counting did it blindly, and were not the same one who analyzed the results. All data are presented as the mean AE standard deviation (SD). Significant differences among groups were determined using unpaired t' test, one-or two-way ANOVA with Tukey-Kramer multiple-comparison test. A value of p < 0.05 was taken as an indication of statistical significance. All figures shown in this article were obtained from at least three independent experiments with similar results.
Results

High STIM1 expression levels associated with poor prognoses in GBM patients
To investigate the role of Stim1 in GBM prognoses, the RNA-Seq data from GBM patients of The Cancer Genome Atlas (TCGA) were analyzed (n = 153). These patients were stratified into high-and low-STIM1 groups based on three quartiles of the STIM1 gene expression levels, including top 25th percentile (first quartile; 75% low and 25% high), 50th percentile (second quantile; 50% low and 50% high), and 75th percentile (third quartile; 25% low and 75% high) cutoff point (Fig. 1a) . Only in the third quartile, significantly fold change and lower overall survival were observed in the high-STIM1 group (n = 115) compared to the low-STIM1 group (n = 38; log-rank test p = 0.032). A Cox regression with forward selection was conducted to investigate whether STIM1 expression levels are an independent prognostic factor by considering other clinical covariates including the Karnofsky performance score, glioma-CpG island methylator phenotype, and methyl guanine methyl transferase promoter methylation (Table 2) . Then, only those covariates with a p value of < 0.05 were included in a further multivariate Cox regression. Results showed that the group with high STIM1 expression levels had worse prognoses compared to the low-STIM1 group (p = 0.011, hazard ratio = 2.28).
STIM1-associated gene signature is enriched in the signaling pathway related to GBM invasiveness To uncover the putative pathological function of Stim1 in GBM patients, high-and low-STIM1 groups stratified by the third quartile were compared using differential gene expression (DEG) analyses. Significant DEGs (with an FDR of < 0.05) between these two groups, containing 814 upregulated (multiple of change of ≥ 1.5 and an FDR of < 0.05) and 100 down-regulated genes (with a multiple of change of ≤ 0.5 and an FDR of < 0.05), were revealed by a heatmap (Fig. 1b) . Then, up-regulated candidate genes were selected to conduct David functional annotation analyses. Significantly enriched pathways were identified (FDR < 0.05, Fig. 1c ) including cytokine and cytokine receptor interactions, extracellular matrix receptor interactions, and focal adhesion. These pathways were reported to Fig. 1 Effects of the over-expression of stromal interacting molecule 1 (Stim1) on glioma progression and cell invasion. (a) Stromal interacting molecule 1 (Stim1) fold change (upper layer) and Kaplan-Meier analyses of patient survival (lower layer) with different expression levels of Stim1 from glioblastoma multiforme RNA-Seq data of The Cancer Genome Atlas (TCGA). Three quartiles including the top 25th percentile (first quartile; 75% low and 25% high), 50th percentile (second quantile; 50% low and 50% high) and 75th percentile (third quartile;; 25% low and 75% high) cut-off point of STIM1 expression were used to categorize patients into high and low STIM1 group, respectively. p values were calculated using the log-rank test (number of patient samples = 153). *p < 0.01. (b) The heatmap shows differentially expressed genes (DEGs) between high and low levels of Stim1 groups with a false discovery rate (FDR) of < 0.05. (c) Significant signaling pathways were analyzed with up-regulated DEGs from the heatmap. Multiples of change in DEGs ≥ 1.5; FDR of < 0.05. (d) The correlation between Stim1 expression and epithelial-to-mesenchymal transition signaling was analyzed by gene enrichment pathway analyses. Gene sets were based on biological processes from the Kyoto Encyclopedia of Genes and Genomes. The detection of endogenous Stim1 protein (e) and mRNA (f) levels in normal human astrocytes and three glioma cell lines. Cells at 80% confluence were grown overnight in serum-containing media. Total lysates were used to, respectively, measure Stim1 protein and mRNA levels by immunoblot assays and real-time PCR assays as described in 'Methods'. Data are expressed as the mean AE SD of three independent experiments (number of cells = 4). After analysis by a one-way ANOVA with the Tukey-Kramer multiple-comparison test, different letters above the bars denote samples that significantly differed (p < 0.05) compared to astrocytes. The over-expression (g) and knockdown (h) effects of Stim1 on glioma U87-MG cell invasion. After cells were transfected with the indicated dose of pcDNA3-Stim1 or Stim1-shRNA for 24 h, changes in cell invasion were measured by Matrigel invasion assays. One microgram of pcDNA3 plasmids or scrambled shRNA was used as the control group. Data are the mean AE SD of four different fields. After analysis by a one-way ANOVA with the Tukey-Kramer multiple-comparison test, different letters above the bars denote samples that significantly differed (p < 0.05) compared to control.
modulate the invasiveness of GBM (Goldbrunner et al. 1999; Wu et al. 2011; Zhu et al. 2012) . Furthermore, by conducting GSEAs (Tables S1 and S2 ), the epithelial-tomesenchymal transition (EMT) was positively associated with STIM1 expression levels (Fig. 1d , normalized enriched score (NES) = 1.7, FDR = 0.01). Furthermore, higher protein and mRNA levels of endogenous Stim1 were observed in three different glioma cell lines compared to normal human astrocytes, especially U87-MG cells ( Fig. 1e and f) . By combining gain-or loss-of function of Stim1 with Matrigel invasion assays, it was found that changes in Stim1 expression levels obviously influenced U87-MG cell invasion abilities ( Fig. 1g and h ). According to these findings, Stim1 might be an important oncogene that regulates GBM progression.
Reduced Stim1 expression is involved in XN-inhibition of glioma cell invasion Previous studies reported that XN, a prenylated chalcone derived from hops, can inhibit cell invasion (Wang et al. 2012b; Kim et al. 2013) , and we also tried to investigate the effects of XN on regulation of glioma cell invasion. First, using 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assays to select a non-cytotoxic concentration of XN on glioma cell viability, we found that treatment with < 20 lM XN showed no significant cell death in either U87-MG or M059K cells ( Figure S1 ). Then, after U87-MG cells were respectively treated with 10 and 20 lM XN for 24 h, significantly reduced levels of cell invasion were observed compared to the untreated group (Fig. 2a) . XN could also reduce M059K cell invasion (Data not shown). However, we observed that M059K cells showed almost less-invasive abilities when comparing with U87-MG cells. It's difficult to conduct all the invasion assays in this study with M059K cells. Therefore, only the U87-MG cells were used in invasion assays. Since XN can reduce cancer cell invasionrelated signaling (Stewart et al. 2015) , we wondered if a relation existed between XN-inhibited cell invasion and Stim1 expression levels. Using immunoblot assays and realtime PCR analyses, we found that XN treatment significantly and dose-dependently decreased endogenous Stim1 protein expressions in both U87-MG and M059K cells (Fig. 2b ), but not mRNA levels (Fig. 2c) . Furthermore, over-expression of Stim1 attenuated XN-reduced U87-MG cell invasion (Fig. 2d) , suggesting that XN-suppressed Stim1 expression is involved in reducing glioma cell invasion.
Up-regulation of miR-4725-3p is involved in XN-mediated glioma cell invasion MiRNAs are small non-coding RNAs which can posttranscriptionally induce translation repression without affecting mRNA cleavage (Macfarlane and Murphy 2010) . Furthermore, in our previous study, we identified the miRNA expression profile in XN-treated U87-MG cells ( Figure S2 ) (Chen et al. 2016) . We proposed that miRNAs might participate in XN-mediated Stim1 expression during cell invasion. By combining analyses of the XN-up-regulated miRNA signature with three target prediction algorithms (Fig. 3a , Table S3 ), only miR-4725-3p was selected as a candidate miRNA. After XN treatment, miR-4725-3p expression levels significantly increased in both U87-MG and M059K cells (Fig. 3b) . Lower endogenous miR-4725-3p levels were also measured in three glioma cell lines compared to normal astrocytes (Fig. 3c) . By over-expressing miR-4725 genes with a non-cytotoxic dose of plasmids in U87-MG cells (≤ 2 lg; Figure S3 ), we found that overexpression of miR-4725 significantly reduced U87-MG cell invasion (Fig. 3d) . Furthermore, over-expression of miR-4725 also enhanced the inhibition of XN-reduced cell invasion (Fig. 3e) . Silence of miR-4725 attenuated XNmediated miR-4725 up-regulation (Fig. 3f) , repressed Stim1 levels (Fig. 3g) , and reduced cell invasions (Fig. 3h) . Taken together, our results suggested that miR-4725-3p plays an important role in XN-mediated cell invasion.
Identification of Stim1 as a direct target gene of miR-4725-3P on regulating cell invasion
Using a TargetScan analysis (Shin et al. 2010), miR-4725-3p was predicted to bind to the Stim1 3 0 UTR (Fig. 4a) . To confirm that Stim1 is a direct target gene of miR-4725-3p, the Stim1 3 0 UTR containing an miR-4725-3p-binding site was cloned into pmiRGlo-dual reporter plasmids. By conducting 3 0 UTR reporter assays with miR-4725 and pmiRGlo-Stim1 3 0 UTR plasmids containing a miR-4725-3p-binding site, we found that miR-4725-3p significantly decreased luciferase activity (Fig. 4b) . To further validate that miR-4725-3p can target the Stim1 3 0 UTR, seven nucleotides located in a critical binding region of the Stim1 3 0 UTR were mutated with mutagenesis by an overlap extension PCR (Fig. 4a) . As shown in Fig. 4(b) , miR-4725 lost the ability to inhibit luciferase activity after mutation of the miR-4725-3p-targeted site. We tested the effect of miR-4725-3p on Stim1 expression and found that over-expression of miR-4725 significantly decreased Stim1 protein expression, but did not influence mRNA levels ( Fig. 4c and d) . Over-expression of Stim1 significantly reversed miR-4725-suppressed U87-MG cell invasion (Fig. 4e) . Furthermore, over-expression of miR-4725 enhanced XN-reduced Stim1 expressions in both U87-MG and M059K cells (Fig. 4f) , suggesting that miR-4725-inhibited Stim1 expression is involved in XN-reduced glioma cell invasion. Finally, to further identify the effect of miR-4725-3p-targeting the 3 0 UTR of Stim1 protein expression and cell invasion, Stim1 cDNA without the 3 0 UTR (Stim1), with the full-length 3 0 UTR (Stim-3U), or with 3 0 UTR containing a mutated miR-4725-3p-targeting site (Stim1-3UM) were, respectively, After analysis by a one-way ANOVA with the Tukey-Kramer multiplecomparison test, different letters above the bars denote samples that significantly differed (p < 0.05) compared to control. Effects of XN on endogenous Stim1 protein (b) and mRNA (c) levels were detected in glioma U87-MG and M059K cells. Cells at 80% confluence were grown overnight in serum-containing media. After XN treatment for another 24 h, total lysates were used to, respectively, measure Stim1 protein and mRNA levels by immunoblotting assays and real-time PCR assays as described in 'Methods'. Data are expressed as the mean AE SD of three independent experiments. (d) Over-expression of Stim1 influenced XNinhibited U87-MG cell invasion. After 2 lg of pcDNA3-Stim1-transfected cells was treated with 20 lM XN for 24 h, changes in cell invasion were measured by Matrigel invasion assays. Two micrograms of the pcDNA3 plasmid was used as the control group. Data are the mean AE SD of four different fields. After analysis by a one-way ANOVA with the Tukey-Kramer multiple-comparison test, different letters above the bars denote samples that significantly differed (p < 0.05) compared to control.
cloned into pcENA3.1 vectors. Using immunoblot analyses and Matrigel invasion assays, Stim1 expression and cell invasion levels were influenced by miR-4725 over-expression only in the Stim1-3U group ( Fig. 4g and h ), suggesting that miR-4725-3p reduced Stim1 protein levels via targeting the 3 0 UTR, resulting in inhibition of glioma cell invasion.
ERK/c-Fos signaling participates in XN-mediated miR-4725-3p up-regulation In our previous study (Chen et al. 2016) , we found that the mitogen-activated protein kinase (MAPK) family, including c-Jun N-terminal kinase (JNK), p38 MAPK, and ERK, plays an important role in XN-mediated cytotoxicity. Next, we tested whether MAPK signaling was also involved in XNup-regulated miR-4725-3p expression. Using MAPK inhibitors, including SB203580 (a p38 MAPK inhibitor), U0126 (an ERK inhibitor), and SP600125 (a JNK inhibitor), we found that only U0126 treatment significantly attenuated XN-regulated miR-4725-3p and Stim1 expression levels ( Fig. 5a and b) . Since XN treatment enhanced ERK and its downstream c-Fos activation in U87-MG cells ( Figure S4 ), we then tested the effects of c-Fos on XN-meditated miR-4725-3p and Stim1 expressions. We found that knockdown of c-Fos expression reduced the ability of XN to regulate miR-4725-3p and Stim1 levels ( Fig. 5c and d) . To identify whether XN enhanced miR-4725-3p expression via transcriptional regulation, we conducted promoter reporter assays with the pGL3 plasmid containing a 2000-bp length of the miR-4725 promoter (chr17:31569142~31571141). As shown in Fig. 5 (e), XN treatment dose dependently increased the luciferase activity. To further identify the core region that is regulated by XN in the miR-4725 promoter, we sequentially truncated the miR-4725 promoter into different lengths. We found that the core region was located in the À1000 to À1500 loci of the miR-4725 promoter (Fig. 5f ). By analysis with the JASPAR database (Mathelier et al. 2016) , a putative c-Fos-binding site was predicted in the À1423 to À1463 region of the miR-4725 promoter (Supplementary Fig. 5 ). By mutating this c-Fos-binding site, luciferase activity was significantly reduced in XN-treated U87-MG cells (Fig. 5g) . Furthermore, results from the ChIP assays also showed that XN treatment significantly improved c-Fos binding to miR-4725 promoter regions (Fig. 5h) . To test whether XN-induced ERK-Fos signaling could regulate STIM1 transcription independent of miR-4725 expression, we re-conducted the ChIP assays. As shown in Figure S6 , XN did not show any effects on c-Fos binding to STIM1 gene promoter. We suggested that XN cannot transcriptionally influence STIM1 gene expression via ERK-Fos signaling. Taken together, the ERK/c-Fos signaling pathway is critical for miR-4725-3p-inhibited Stim1 expression in XNreduced glioma cell invasion.
Discussions
The SOCE pathway was identified to play critical roles in tumorigenesis, tumor neovascularization, metastasis, and invasion (Zhu et al. 2014) . Since Stim1 acts as a major regulator of the SOCE pathway and is considered a novel target for cancer therapy (Zhu et al. 2014; Vashisht et al. 2015) , it is important to clarify the role of Stim1 in cancer progression, especially in glioma invasion. By analyzing the RNA-Seq data of TCGA GBM patients, patients with high Stim1 expression levels correlated with the poor prognoses compared to the low-Stim1 group. Stim1-correlated genes were significantly associated with glioma invasion-related pathways, such as the EMT and focal adhesion. Elevated Stim1 expression was observed in glioma cell lines compared to human astrocytes, and was related to the invasive ability of glioma cells. All those findings suggest that Stim1 acts as an oncogenic regulator in enhancing glioma cell invasion. Furthermore, we found that XN, a prenylated chalcone derived from hops, significantly reduced Stim1 levels and thus inhibited glioma cell invasion. Up-regulation of miR- 4725-3p by XN treatment directly targeted the Stim1 3 0 UTR and suppressed Stim1 expression (Fig. 5i) . As a consequence, miR-4725-3p targeting of Stim1 expression plays an important role in XN's inhibition of glioma cell invasion.
Increasing evidence indicates that Stim1-regulated physiological functions result in cancer process. Further investigating Stim1-mediated downstream signaling to explore cancer progression is still an important issue. Stim1 enhanced colorectal cancer cell migration (Wang et al. 2015) via cyclooxygenase-2 gene activation (Huang et al. 2011; Wang et al. 2012a ) and gastric cancer progression (Xia et al. 2016) . In gliomas, Stim1 was suggested to play an essential role in regulating cell invasion (Motiani et al. 2013) , similar to our findings here. In addition, we further identified that GBM patients with high Stim1 levels had poor survival rates. Up-regulated genes in the high-Stim1 group were involved in invasion-related signaling pathways, including cytokinecytokine receptor interactions, extracellular matrix-receptor interactions, cell adhesion molecules, and focal adhesion. In the GSEAs, EMT signaling showed a significant correlation with high Stim1 expression. Indeed, our results are consistent with the previous studies in the colorectal cancer (Wong and Chang 2015) .
In addition to Stim1 downstream signaling, the mechanisms regulating Stim1 gene expression levels also influence cellular processes. In addition to traditional signaling, microRNA has been reported to regulate Stim1 expression. For example, miR-185 post-transcriptionally targets and inhibits Stim1 levels in colorectal cancer metastasis (Zhang et al. 2015) . In this study, we found that XN significantly reduced Stim1-mediated glioma cell invasion and confirmed that Stim1 is a direct target gene of miR-4725-3p, which was up-regulated in XN-inhibited cell invasion. However, we found that mutation of the predicted miR-4725-targeting site did not completely abolish the effect of miR-4725 on luciferase activity with 3 0 UTR reporter assays (Fig. 4b) . We suggest that another un-predicted putative miR-4725 binding site in STIM1 3 0 UTR or an unknown mechanism may also exist in miR-4725-inhibited STIM1 expressions, which needs further investigation in the future. Taken together, our data indicated that miR-4725-3p may act as a tumor suppressive miRNA in the glioma process.
XN can possess multiple functions in regulating different physiological conditions. In cancers, most studies of XN focused on its anti-proliferative functions. XN is able to inhibit NF-jB signaling, activate MAPK pathways, and induce oxidative stress in promoting cell apoptosis (Colgate et al. 2007; Festa et al. 2011; Blanquer-Rossello et al. 2013) . In this study, using treatment at a non-cytotoxic dose, XN also significantly reduced glioma cell invasion. Furthermore, miR-4725-3p targeting of Stim1 signaling was validated to participate in suppression of invasion by XN. In addition to miR-4725-3p, elevated miR-204-3p levels were also reported to exhibit XN cytotoxicity (Chen et al. 2016) , suggesting that variant miRNAs play critical roles in XNmediated downstream signaling.
Several miRNAs were reported to regulate glioma cell invasion. However, the function and role of miR-4725-3p in gliomas still remain an unexplored field. Furthermore, definitively clarifying the mechanisms that influence expressions of these miRNAs is also important for research on glioma cell invasiveness. Nevertheless, some limitations still exist in our study. It was difficult to collect sufficient clinical patient samples or find a suitable public database to evaluate 
Open Science Badges
This article has received a badge for *Open Materials* because it provided all relevant information to reproduce the study in the manuscript. The complete Open Science Disclosure form for this article can be found at the end of the article. More information about the Open Practices badges can be found at https://cos.io/our-services/open-science-badges/.
The immunoblotting raw data are presented in the online supplementary files. All the data will be provided upon request.
Supporting information
Additional Supporting Information may be found online in the Supporting Information section at the end of the article. Figure S1 . Effects of different dose of Xanthohumol (XN) treatment on glioma cell cytotoxicity. Figure S2 . Heatmap demonstrated XN-regulated microRNA profiles in U87-MG cells. Figure S3 . Effects of different dose of miR-4725 transfection on glioma cell cytotoxicity. Figure S4 . XN treatment enhanced phosphorylation of ERK and c-Fos. Figure S5 . The position-weighted matrix showed putative c-Fosbinding sequence and binding site (red color) predicted by the JASPAR database. Figure S6 . XN showed no effects on c-Fos binding to the STIM1 promoter. Effects of mitogen-activated protein kinase inhibitors including U0126 (an ERK inhibitor), SB203580 (a p38 inhibitor), and SP600125 (a c-Jun N-terminal kinase inhibitor) on XN-induced miR-4725 levels (a) and XN-reduced stromal interacting molecule 1 (Stim1) expressions (b). After U87-MG cells were, respectively, pre-treated with 10 lM U0126, 5 lM SB203580, and 10 lM SP600125 for 1 h, 20 lM XN was added for another 24 h, and endogenous miR-4725-3p and Stim1 protein levels were, respectively, measured by a real-time PCR and an immunoblotting assay. The U6B level was used as an internal control. Data are the mean AE SD of three experiments. Asterisks indicate statistically significant difference between control without treatment and treatment group. XN treatment with inhibitors were compared to the XN treatment group (#p < 0.05) in two-way ANOVA with TukeyKramer multiple-comparison test. Knockdown of c-Fos abolished XNmediated miR-4725 (b) and Stim1 (c) protein levels. After U87-MG cells were, respectively, transfected with 2 lg c-Fos shRNA and scrambled shRNA for 24 h, 20 lM XN was added for another 24 h. Endogenous miR-4725-3p and Stim1 protein levels were, respectively, measured by a real-time PCR and an immunoblotting assay. The U6B level was used as an internal control. Data are the mean AE SD of three experiments. Asterisks indicate statistically significant difference between control without treatment and treatment group. Table S1 . The activated pathways associated with high STIM1 expression levels .  Table S2 . The inhibited pathways associated with high STIM1 expression levels. Table S3 . List of significant XN-up-regulated microRNAs (p value ≤ 0.01). [] Please check this box if you are interested in participating.
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